|
1) Teramoto S, Yamamoto H, Yamaguchi Y, et al. Global burden of COPD in Japan and Asia. Lancet. 2001; 362: 1764-5
|
|
|
|
|
2) Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome？ Lancet. 2007; 370: 797-9
|
|
|
|
|
3) Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006; 47: 2554-60
|
|
|
|
|
|
4) Soyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007; 29: 279-83
|
|
|
|
|
|
5) van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol. 2008; 102: 192-6
|
|
|
|
|
|
6) Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007; 131: 1006-12
|
|
|
|
|
|
7) Ishida W, Kajiwara T, Ishii M, et al. Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: a population-based analysis in Japan. Tohoku J Exp Med. 2007; 212: 265-73
|
|
|
|
|
8) Blamoun AI, Batty GN, Debari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008; 62: 1373-8
|
|
|
|
|
|
9) Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest. 2007; 132: 1764-71
|
|
|
|
|
|
10) Lee TM, Lin MS, Chang NC. Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol. 2008; 101: 530-5
|
|
|
|
|
|
11) Melbye H, Halvorsen DS, Hartz I, et al. Bronchial airflow limitation, smoking, body mass index, and statin use are strongly associated with the C-reactive protein level in the elderly. The Tromso Study 2001. Respir Med. 2007; 101: 2541-9
|
|
|
|
|
|
12) Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009; 10: 45
|
|
|
|
|
|
13) Merx MW, Weber C. Statins in the intensive care unit. Curr Opin Crit Care. 2006; 12: 309-14
|
|
|
|
|
|
14) Hurst JR, Hagan G, Wedzicha JA. Mechanism of statin-associated mortality reduction in COPD. Chest. 2007; 132: 1409
|
|
|
|
|
|
15) Morimoto K, Janssen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol. 2006; 176: 7657-65
|
|
|
|
|
|
16) Walsh G. Statins as emerging treatments for asthma and chronic obstructive pulmonary disease. Expert Rev Resp Med. 2008; 2: 329-35
|
|
|
|
|
|
17) Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005; 172: 987-93
|
|
|
|
|
|
18) Takahashi S, Nakamura H, Seki M, et al. Reversal of elastase-induced pulmonary emphysema and promotion of alveolar epithelial cell proliferation by simvastatin in mice. Am J Physiol Lung Cell Mol Physiol. 2008; 294: L882-90
|
|
|
|
|
|
19) Janda S, Park K, FitzGerald JM, et al. Statins in COPD. Chest. 2009. http://www.chestjournal.org/content/early/2009/04/17/chest.09-0194
|
|
|
|
|
|
20) Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulmonary Medicine. 2009, 9: 32-44
|
|
|
|
|
|
21) Effect of statins on asthma control in smokers with asthma＋pilot study of effect of statins on lung function in COPD. http://www.clinicaltrials.gov/ct2/show/NCT00463827？term＝COPD＋and＋Statins&rank＝1
|
|
|
|
|
|
22) Effect of statin therapy on C-reactive protein levels in patients with chronic obstructive lung fisease (COPD). http://www.clinicaltrials.gov/ct2/show/NCT00655993？term＝COPD＋and＋Statins&rank＝2
|
|
|
|
|
|
23) Simvastatin in chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/NCT00680641？term＝COPD＋and＋Statins&rank＝5
|
|
|
|
|
|
24) Lovastatin as a potential modulator of apoptosis in chronic obstructive pulmonary disease (COPD). http://www.clinicaltrials.gov/ct2/show/NCT00700921？term＝COPD＋and＋Statins&rank＝4
|
|
|
|
|